Document:

Assignment, Assumption and Amendment Agreement

 EXHIBIT 4.2E 
 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT 

THIS ASSIGNMENT, ASSUMPTION AND AMENDMENT
AGREEMENT (the “Agreement”) is made effective as of the Effective Time, by and among JAZZ PHARMACEUTICALS, INC., a Delaware corporation
(“JPI”), JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (f/k/a Azur Pharma Public Limited Company), a public limited company formed under the laws
of Ireland (“New Jazz”), and the undersigned Holders (the “Consenting Holders”). 
 RECITALS 
 WHEREAS, JPI and the
Investors are parties to that certain Third Amended and Restated Investor Rights Agreement made effective as of June 6, 2007 and as amended (as amended, the “Investor Rights Agreement”). 

WHEREAS, JPI, New Jazz, Jaguar Merger Sub Inc., a Delaware corporation and wholly owned subsidiary
of New Jazz (“Merger Sub”), and Seamus Mulligan, solely in his capacity as the representative for the Indemnitors, entered into an Agreement and Plan of Merger and Reorganization, dated as of September 19, 2011 (the
“Merger Agreement”), pursuant to which, among other things, Merger Sub will merge with and into JPI (the “Merger”), with JPI as the surviving corporation in the Merger as a wholly owned subsidiary of
New Jazz. At the Effective Time, among other things, (x) each share of the Common Stock, par value $0.0001 per share, of JPI (“JPI Common Stock”) then issued and outstanding will be canceled and automatically converted
into and become the right to receive one Ordinary Share, nominal value $0.0001 per share, of New Jazz (“New Jazz Ordinary Shares”) and (y) each warrant to acquire JPI Common Stock outstanding as of immediately prior to
the Effective Time will be converted into a warrant to acquire the number of New Jazz Ordinary Shares equal to the number of shares of JPI Common Stock subject to such warrant immediately prior to the Effective Time, at an exercise price per New
Jazz Ordinary Share equal to the exercise price per share of JPI Common Stock otherwise purchasable pursuant to such warrant. 
 WHEREAS, the Consenting Holders acknowledge that New Jazz has entered or intends to enter into a Registration Rights Agreement in substantially the form attached as Exhibit A hereto
(the “Azur Rights Agreement”) with the shareholders of New Jazz prior to the Merger (the “Azur Rights Holders”) in connection with the transactions contemplated by the Merger Agreement, pursuant to
which New Jazz is obligated to (i) prepare and file one or more registration statements (the “Resale Registration Statements”) under the Securities Act of 1933, as amended (the “Securities Act”),
registering the resale of all of the New Jazz Ordinary Shares (the “Resale Shares”) held by the Azur Rights Holders (or any transferees or assignees thereof) on the Closing Date as set forth in Section 2.1(a) of the Azur
Rights Agreement and (ii) subject to certain conditions and limitations set forth therein, take certain actions to effect the issuance and sale of Resale Shares in underwritten public offerings (“Required Underwritings”)
as set forth in Section 2.1(f) of the Azur Rights Agreement. As used in this Agreement, (x) the term “Resale Shares” also includes any securities issued or issuable with respect to any of the Resale Shares by way of
exchange, stock dividend or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization or otherwise; and (y) the term “Resale Registration Statement”
includes (A) any registration statements filed by New Jazz under the Securities Act in furtherance of satisfying its obligations under the Azur Rights Agreement and (B) any amendments or supplements to any of such registration statements
or the prospectuses included therein. 
 WHEREAS, pursuant to Section 4 of the
Investor Rights Agreement, the Holders have under certain circumstances the right to be notified if JPI decides to Register any JPI Common Stock and to include certain Registrable Securities held by such Holders in such Registration (and any related

  
 1 

 
qualification under Blue Sky laws or other compliance), and in any underwriting involved therein (the “Piggyback Registration Rights”). 

WHEREAS, JPI, New Jazz and the Consenting Holders wish to enter into this Agreement for the purpose
of (i) transferring the rights and obligations of JPI under the Investor Rights Agreement to New Jazz, effective as of the Effective Time (the “Assignment”), (ii) effecting certain waivers of rights as set forth
below and (iii) amending the Investor Rights Agreement as set forth below. 
 WHEREAS,
the Consenting Holders are holders of at least 60% of the Registrable Securities held by all Holders and, together with JPI, have the right, pursuant to Section 15.5 of the Investor Rights Agreement, to amend the Investor Rights Agreement
and to waive certain provisions thereof. 
 NOW, THEREFORE, in
consideration of the mutual agreements, covenants and considerations contained herein, the parties hereto agree as follows: 

AGREEMENT 
 1.     DEFINITIONS. The term “Effective Time” shall have the meaning set forth in the Merger Agreement. Any other capitalized terms used
herein and not otherwise defined shall have the meanings set forth in the Investor Rights Agreement. 
 2.
    ASSIGNMENT AND ASSUMPTION. Effective as of the Effective Time: 
 2.1         JPI hereby conveys, transfers and assigns to New Jazz all of JPI’s rights and obligations under the Investor Rights Agreement, as hereby
amended (the “Assignment”). 
 2.2
        New Jazz hereby assumes the rights and agrees to perform the obligations of JPI (as “the Company” or otherwise) under the Investor Rights Agreement, as hereby amended. 

2.3         All references to shares of JPI Common Stock in the Investor
Rights Agreement shall be deemed to be references to, as applicable, (x) with respect to shares of JPI Common Stock outstanding as of immediately prior to the Effective Time, the New Jazz Ordinary Shares into which such shares of JPI Common
Stock were automatically converted at the Effective Time, (y) with respect to shares of JPI Common Stock issuable upon the exercise of warrants to purchase JPI Common Stock outstanding as of immediately prior to the Effective Time, the New Jazz
Ordinary Shares issuable upon exercise thereof following the Effective Time or (z) with respect to any other shares of JPI Common Stock referenced in the Investor Rights Agreement that were not outstanding immediately prior to the Effective
Time, New Jazz Ordinary Shares. 
 3.     CONSENT TO
ASSIGNMENT. The Consenting Holders, for and on behalf of all Holders and all Investors, hereby consent to the Assignment. In connection therewith, the Consenting Holders, for and on behalf of all
Holders and all Investors, hereby agree that the indemnification rights of JPI (as “the Company” or otherwise) under the Investor Rights Agreement shall be enforceable by New Jazz effective as of the Effective Time. 

4.     CONSENT TO AZUR RIGHTS
AGREEMENT. The Consenting Holders, for and on behalf of all Holders and all Investors, hereby consent to the entering into of the Registration Rights Agreement by New Jazz and the grant to the Azur Rights Holders of
Registration rights pursuant thereto. 
 5.     WAIVERS. 

  
 2 

 5.1         The Consenting
Holders hereby irrevocably waive, for and on behalf of all Holders and all Investors, (i) any and all Piggyback Registration Rights in connection with the filing of any Resale Registration Statement from the period beginning as of the Effective
Time through the Deferral Date (as defined below) (the “Deferral Period”) and (ii) any rights to any notices with respect to the foregoing under the Investor Rights Agreement. In granting the foregoing waiver, the
Consenting Holders acknowledge and understand that JPI and New Jazz currently contemplate that New Jazz will file a WKSI Shelf Registration Statement (if it is then eligible to do so) as soon as reasonably practicable following the Merger
registering an indeterminate number of securities of New Jazz and pursuant to which New Jazz will effect the Registration of the Resale Shares (the “Closing S-3ASR”). For the avoidance of doubt and subject to the following
proviso, the Consenting Holders, for and on behalf of all Holders and all Investors, agree that the foregoing waiver shall also apply to the filing of the Closing S-3ASR and any supplements to the prospectus included therein solely with respect to
any of the Resale Shares; provided, however, that following the Deferral Date (as defined below), the Holders may exercise their Piggyback Registration Rights to include Registrable Securities in the Closing S-3ASR or any
post-effective amendment thereto. 
 5.2         The Consenting
Holders hereby further irrevocably waive, for and on behalf of all Holders and all Investors, on the limited basis set forth in this Section 5.2, (i) any and all Piggyback Registration Rights in connection with any Required Underwriting,
the underwriting agreement for which is entered into prior to the Deferral Date (an “Excluded Underwriting”) and (ii) any rights to any notices with respect to any Excluded Underwriting under the Investor Rights
Agreement. The waiver in this Section 5.2 is limited to Excluded Underwritings and nothing in this Agreement (including Sections 5.1 and this 5.2 hereof) shall constitute or shall be deemed to constitute a waiver of any Piggyback Registration
Rights in connection with any Required Underwriting that is not an Excluded Underwriting. 
 5.3
        The foregoing waivers in Sections 5.1 and 5.2 are irrevocable and shall be effective with respect to each Holder and each Investor, as well as all affiliates, successors, heirs, executors,
administrators and assigns of each such Holder and Investor. 
 6.
    DEFERRAL OF REQUESTS FOR REGISTRATION. The Consenting Holders, for and on behalf of all Holders and all Investors, hereby agree
that New Jazz shall not be obligated to effect any Registration under the Investor Rights Agreement or to include any Registrable Securities in any Registration Statement filed by New Jazz, in each case until after February 14, 2012 (such date,
the “Deferral Date”). In furtherance of the foregoing, each Consenting Holder hereby agrees (i) not to exercise any of its rights to demand or cause New Jazz to Register any securities under the Investor Rights Agreement
(including under Sections 3 and 4 thereof), or to include Registrable Securities in any Registration Statement filed by New Jazz, in each case until after the Deferral Date and (ii) not to transfer any of such Consenting Holder’s
Registration rights under the Investor Rights Agreement unless the transferee agrees in a writing, reasonably satisfactory in form and substance to New Jazz, to be bound by the terms of this Section 6 until after the Deferral Date. 

7.     MISCELLANEOUS. 

7.1         Full Power and Authority. Each Consenting Holder represents
and warrants to JPI and New Jazz that (i) such Consenting Holder has the full right, power and authority to execute and deliver this Agreement, and (ii) this Agreement has been duly executed and delivered by such Consenting Holder and
constitutes the legal, valid and binding obligation of such Consenting Holder enforceable in accordance with its terms, except (A) as such enforcement is limited by bankruptcy, insolvency or other similar laws affecting the enforcement of
creditors’ rights generally and (B) for limitations imposed by general principles of equity. Each of JPI and New Jazz represent and warrant to the undersigned Holders that (i) JPI and New Jazz, as applicable, has the full right, power
and authority to execute and deliver this 

  
 3 

 
Agreement, and (ii) this Agreement has been duly executed and delivered by JPI and New Jazz, as applicable, and constitutes the legal, valid and binding obligation of JPI and New Jazz, as
applicable, enforceable in accordance with its terms, except (A) as such enforcement is limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally and (B) for limitations imposed
by general principles of equity. 
 7.2         Effect of Agreement.
This Agreement shall become effective as of the Effective Time. Except as modified by the terms of this Agreement, the terms and provisions of the Investor Rights Agreement shall remain in full force and effect. Other than as stated in this
Agreement, this Agreement shall not operate as a waiver of any condition or obligation imposed on the parties under the Investor Rights Agreement. In the event of any conflict, inconsistency, or incongruity between any provision of this Agreement
and any provision of the Investor Rights Agreement, the provisions of this Agreement shall govern and control. This Agreement shall not be changed or modified orally, but only by an instrument in writing signed by the parties hereto. 

7.3         Governing Law. This Agreement shall be governed by, and
construed in accordance with, the laws of the State of California excluding those laws that direct the application of the laws of another jurisdiction. 
 7.4         Successors and Assigns. The provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and
administrators of the parties hereto and each Holder and Investor, and shall be enforceable by New Jazz or any Holder or Investor. 
 7.5         Counterparts. This Agreement may be executed in several counterparts, each of which shall constitute an original and all of which, when taken
together, shall constitute one instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 4 

 IN WITNESS WHEREOF, the
undersigned have executed this ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT on this 18th day of January, 2012. 

JPI: 

JAZZ PHARMACEUTICALS, INC. 
 Signature:  /s/ Bruce C.
Cozadd                             

Print Name:  Bruce C.
Cozadd                                 

Title:  Chairman & Chief Executive Officer         

  
 [SIGNATURE
PAGE TO ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT] 

 IN WITNESS WHEREOF, the
undersigned have executed this ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT on this 18th day of January, 2012. 

 

			
	 NEW JAZZ:

 
 JAZZ PHARMACEUTICALS PUBLIC LIMITED
COMPANY

	
	 Signature:  /s/ David
Brabazon                            

	
	 Print Name:  David
Brabazon                                

	
	 Title:  Senior Vice President,
Finance                  

  
 [SIGNATURE
PAGE TO ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT] 

 IN WITNESS WHEREOF, the
undersigned have executed this ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT on this 18th day of January, 2012. 

HOLDERS: 
  

			
	 KKR JP LLC

	
	 Signature:  /s/ James
Momtazee                            

	
	 Print Name:  James
Momtazee                                

	
	 Title:  Vice
President                                        
        

  

	
	 KKR JP III LLC

	
	Signature:  /s/
James Momtazee                            
	
	Print Name:  James
Momtazee                                
	
	Title:  Vice President                       
                         

  
 [SIGNATURE
PAGE TO ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT] 

 IN WITNESS WHEREOF, the
undersigned have executed this ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT on this 18th day of January, 2012. 

HOLDERS: 
  

			
	 VERSANT VENTURE CAPITAL II, L.P.

		
	 By:
  

 
	 	 Versant Ventures II, L.L.C.,
 its General Partner

	
	 Signature:  /s/ Samuel D.
Colella                                

	
	Print Name:  Samuel D. Colella                  
                  
	
	Title:       Managing
Director                                        

  

			
	 VERSANT SIDE FUND II, L.P. 

		
	 By:
  

 
	 	 Versant Ventures II, L.L.C.,
 its General Partner

 
	
	
	 Signature:  /s/ Samuel D.
Colella                                

	
	Print Name:  Samuel D. Colella                    
                
	
	Title:       Managing
Director                                        

  

			
	 VERSANT AFFILIATES FUND II-A, L.P. 

		
	 By:
  

 
	 	 Versant Ventures II, L.L.C.,
 its General Partner

 
	
	
	 Signature:  /s/ Samuel D.
Colella                                

	
	Print Name:  Samuel D. Colella                    
                
	
	Title:       Managing
Director                                        

  
 [SIGNATURE
PAGE TO ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT] 

 IN WITNESS WHEREOF, the
undersigned have executed this ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT on this 13th day of January, 2012. 

HOLDERS: 
  

			
	 THOMA CRESSEY FUND VII, L.P.

		
	 By:
	 	 TC Partners VII, L.P.

	 Its:
	 	 General Partner

		
	 By:
	 	 Thoma Cressey Bravo Inc.

	 Its:
	 	 General Partner
  

 
	
	 Signature:  /s/ Bryan Cressey
                                

	
	Print Name:  Bryan Cressey                      
               
	
	Title:       Partner                    
                                     

  

			
	 THOMA CRESSEY FRIENDS FUND VII, L.P.

		
	 By:
	 	 TC Partners VII, L.P.

	 Its:
	 	 General Partner

		
	 By:
	 	 Thoma Cressey Bravo Inc.

	 Its:
	 	 General Partner
  

 
	
	 Signature:  /s/ Bryan Cressey
                                

	
	Print Name:  Bryan Cressey                      
               
	
	Title:       Partner                    
                                     

  
 [SIGNATURE
PAGE TO ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT] 

 EXHIBIT A 
 AZUR RIGHTS AGREEMENT 

  
 EXHIBIT AForm of Jazz Pharmaceuticals plc Warrant to Purchase Ordinary Shares

 EXHIBIT 4.3 
 THE SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE
SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED. 
  

			
	Warrant No.: [   ]	  	Number of Shares: [         ]
	Date of Issuance: January 18, 2012	  	(subject to adjustment)

 JAZZ PHARMACEUTICALS PLC 
 Warrant To Purchase Ordinary Shares 
 This Warrant
No. [            ] (this “Warrant”) of Jazz Pharmaceuticals plc, an Irish incorporated public limited company (the “Company”), for value received, hereby
certifies that [                        ], the holder of this Warrant, or its registered assigns (the “Registered
Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at any time after the date hereof and on or before the Expiration Date (as defined in Section 6 below), up to
[                ] ordinary shares of US$0.0001 each in the capital of the Company (“Ordinary Shares”), at a purchase price of $9.34 per share. The
shares purchasable upon exercise of this Warrant and the purchase price per share, as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Stock” and the
“Purchase Price,” respectively. 
 1. Exercise. 

(a)      Manner of Exercise. This Warrant may be exercised by the Registered
Holder, in whole or in part, by surrendering this Warrant, with the exercise form appended hereto as Exhibit A duly executed by such Registered Holder, at the principal office of the Company, or at such other office or agency as the Company
may designate, accompanied by payment in full of the Purchase Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise. The Purchase Price may be paid by cash, cheque, or wire transfer to an account designated
in writing by the Company. 
 (b)      Effective Time of
Exercise. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 1(a) above. At
such time, the person or persons in whose name or names any certificates for Warrant Stock shall be issuable upon such exercise as provided in Section 1(c) below shall be deemed to have become the holder or holders of record of the Warrant
Stock represented by such certificates. 
 (c)      Delivery to
Registered Holder. As soon as practicable after the exercise of this Warrant in whole or in part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and

 
delivered to, the Registered Holder, or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct: 

(i) a certificate or certificates for the number of shares of Warrant Stock to which such Registered Holder shall be
entitled, and 
 (ii) in case such exercise is in part only, a new warrant or warrants (dated the date hereof)
of like tenor, calling in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment therein) to the number of such shares called for on the face of this Warrant minus the
number of such shares purchased by the Registered Holder upon such exercise as provided in Section 1(a) above. 
 2. Adjustments. 

(a)      Stock Splits and Dividends. If the outstanding shares of Warrant
Stock shall be subdivided into a greater number of shares or a dividend in Warrant Stock shall be paid in respect of Warrant Stock, the Purchase Price in effect immediately prior to such subdivision or at the record date of such dividend shall
simultaneously with the effectiveness of such subdivision or immediately after the record date of such dividend be proportionately reduced. If outstanding shares of Warrant Stock shall be combined into a smaller number of shares, the Purchase Price
in effect immediately prior to such combination shall, simultaneously with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Purchase Price, the number of shares of Warrant Stock
purchasable upon the exercise of this Warrant shall be changed to the number determined by dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment, multiplied by the
Purchase Price in effect immediately prior to such adjustment, by (ii) the Purchase Price in effect immediately after such adjustment. 
 (b)      Reclassification, Etc. In case there occurs any reclassification or change of the outstanding securities of the Company or of any reorganization of the
Company (or any other corporation the stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization on or after the date hereof, then and in each such case the Registered Holder,
upon the exercise hereof at any time after the consummation of such reclassification, change, or reorganization, shall be entitled to receive, in lieu of the stock or other securities and property receivable upon the exercise hereof prior to such
consummation, the stock or other securities or property to which such Registered Holder would have been entitled upon such consummation if such Registered Holder had exercised this Warrant immediately prior thereto, all subject to further adjustment
pursuant to the provisions of this Section 2. 
 (c)      Adjustment
Certificate. When any adjustment is required to be made in the Warrant Stock or the Purchase Price pursuant to this Section 2, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief
statement of the facts requiring such adjustment, (ii) the Purchase Price after such adjustment and (iii) the kind and amount of stock or other securities or property into which this Warrant shall be exercisable after such adjustment.

 3. Transfers. 

(a)      Unregistered Security. Each holder of this Warrant acknowledges
that this Warrant and the Warrant Stock have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and agrees that in no event will it dispose of all or any portion of this Warrant or the Warrant
Stock unless and until (a) it has complied with the provisions of Section 3(b) below, and (b) if reasonably requested by the 

 
Company, the Registered Holder shall have furnished the Company with an opinion of counsel reasonably satisfactory in form and substance to the Company and the Company’s counsel to the
effect that (x) such disposition will not require registration under the Securities Act and (y) appropriate action necessary for compliance with the Securities Act and any applicable state, local, or foreign law has been taken. Without
limiting the foregoing, the Registered Holder, by accepting this Warrant, agrees that it may transfer this Warrant (or any portion hereof) only to one of its Affiliates (as defined in the Senior Secured Note and Warrant Purchase Agreement, dated
June 24, 2005, by and among Jazz Inc. and the initial holders of the Series BB Warrants (the “Purchase Agreement”) or to any other person or entity that is acceptable to the Company, provided that, in the case of any transfer, the
applicable transferee must agree in writing to be subject to the terms of this Warrant and the Investor Rights Agreement (as such terms are defined below); provided, however, that, except with respect to transfers to its Affiliates,
the Registered Holder hereby covenants not to effect such transfer if such transfer either would invalidate the securities laws exemptions pursuant to which this Warrant was originally offered and sold or would itself require registration and/or
qualification under the Securities Act or applicable state securities laws. Each certificate evidencing this Warrant transferred as provided above shall bear an appropriate restrictive legend substantially to the foregoing effect. 

For purposes of this Warrant, “Investor Rights Agreement” means that certain Third Amended and Restated
Investor Rights Agreement, dated as of June 6, 2007, by and among Jazz Pharmaceuticals, Inc. (“Jazz Inc”), the investors in Jazz Inc’s Series A Preferred Stock, Series B Preferred Stock and Series B Prime Preferred Stock,
the holders of the Common Stock Warrants (and any shares issued upon exercise of such warrants) and certain other holders of Ordinary Shares, as amended. 
 (b)      Transferability. Subject to the provisions of this Section 3 and the provisions of Section 5, this Warrant and all rights hereunder are
transferable, in whole or in part, upon surrender of the Warrant with a properly executed assignment in the form of Exhibit B hereto at the principal office of the Company. Any purported transfer of all or any portion of this Warrant in
violation of the provisions of this Warrant shall be null and void. 

(c)      Warrant Register. The Company will maintain a register containing
the names and addresses of the Registered Holders of this Warrant and all other Ordinary Share Warrants. Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant as the absolute
owner hereof for all purposes; provided, however, that if this Warrant is properly assigned in blank, the Company may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding
any notice to the contrary. Any Registered Holder may change such Registered Holder’s address as shown on the warrant register by written notice to the Company requesting such change. 

4. Representations and Warranties of the Registered Holder. The Registered Holder hereby represents and
warrants to the Company that: 
 (a)      Authorization. The
Registered Holder has full power and authority to enter into, and perform its obligations under, this Warrant. This Warrant, when executed and delivered by the Registered Holder, will constitute a valid and legally binding obligation of the
Registered Holder, enforceable in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of
creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 
 (b)      Purchase Entirely for Own Account. This Warrant is issued to 

 
the Registered Holder in reliance upon the Registered Holder’s representation to the Company, which by the Registered Holder’s acceptance of this Warrant, the Registered Holder hereby
confirms, that the Warrant to be acquired by the Registered Holder and the Warrant Stock (collectively, the “Securities”) will be acquired for investment for the Registered Holder’s own account, not as a nominee or agent, and
not with a view to the resale or distribution of any part thereof, and that the Registered Holder has no present intention of selling, granting any participation in, or otherwise distributing the same. By accepting this Warrant, the Registered
Holder further represents that the Registered Holder does not presently have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of
the Securities. The Registered Holder has not been formed for the specific purpose of acquiring the Securities. 
 (c)      Disclosure of Information. The Registered Holder has had an opportunity to discuss the Company’s business, management, financial affairs and the
terms and conditions of the offering of the Securities with the Company’s management and has had an opportunity to review the Company’s facilities. The Registered Holder understands that such discussions, as well as any written information
delivered by the Company to the Registered Holder, were intended to describe the aspects of the Company’s business which it believes to be material. 
 (d)      Restricted Securities. The Registered Holder understands that the Securities have not been, and will not be, registered under the Securities Act, by
reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Registered Holder’s representations as expressed
herein. The Registered Holder understands that the Securities are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Registered Holder must hold the Securities indefinitely
unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Registered Holder acknowledges that the Company has no
obligation to register or qualify the Securities for resale. The Registered Holder further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited
to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Registered Holder’s control, and which the Company is under no obligation and may not be able to
satisfy. 
 (e)      Accredited Investor. The Registered Holder is
an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 
 5. Market Standoff.  

(a)      Market Standoff. The Registered Holder hereby agrees that, if so
requested by the Company and the Underwriter’s Representative (as defined below), if any, the Registered Holder shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise transfer or dispose of this Warrant
or other securities of the Company (“Market Standoff) without the prior written consent of the Company and the Underwriter’s Representative for such period of time commencing with the date the Company provides notice to the
Registered Holder of a proposed follow-on offering and ending 90 days after the effective date of the Registration Statement or, in the event of a shelf registration, the date of the prospectus for such follow-on offering, as may be requested by the
Underwriter’s Representative; provided, however, that the Registered Holder shall not be required to agree to a Market Standoff for a period of time that commences less than thirty (30) days after the expiration of another period of time
during which the Registered Holder has agreed to a Market Standoff. The obligations of the Registered Holder under this Section 5 shall be conditioned upon similar agreements 

 
being in effect with each other stockholder of the Company who is an executive officer or director of the Company. For purposes of this Warrant, the “Underwriter’s
Representative” is the representative the underwriter or underwriters selected for the underwriting of a public offering of the Company’s securities. 

(b)      Stop-Transfer Instructions. In order to enforce the covenants set
forth in Section 3 and Section 5(a), the Company may impose stop-transfer instructions with respect to the securities of the Registered Holder (and the securities of every other person subject to the restrictions in Section 3 and
Section 5(a)). 
 6. Termination. This Warrant (and the right to purchase securities upon
exercise hereof) shall terminate on June 24, 2012 (the “Expiration Date”). 
 7.
Notices of Certain Transactions. In the event that the Company shall propose at any time to: 

(a)    declare any dividend or distribution upon the Ordinary Shares, whether in cash, property,
stock, or other securities, whether or not a regular cash dividend and whether or not out of earnings or earned surplus; 
 (b)    offer for subscription pro rata to the holders of any class or series of its stock any additional shares of stock of any class or series or other rights; 

(c)    effect any reclassification or recapitalization of the Ordinary Shares outstanding involving
a change in the Ordinary Shares; 
 (d)    merge or consolidate with or into any other
partnership, corporation, business trust, joint stock company, trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature; or 

(e)    sell, lease, or convey all or substantially all its assets, property or business, or to
liquidate, dissolve, or wind up the Company; then, in connection with each such event, the Company shall send to the Registered Holder (in accordance with the provisions of Section 23): 

(i) at least twenty (20) days’ prior written notice of the date on which a record shall be taken for such
dividend, distribution or subscription rights (and specifying the date on which the holders of Ordinary Shares shall be entitled thereto) or for determining rights to vote in respect of the matters referred to in (c), (d) and (e) above;
and 
 (ii) in the case of the matters referred to in (c), (d) and (e) above, at least 20 days’
prior written notice of the date when the same shall take place (and specifying the date on which the holders of Ordinary Shares shall be entitled to exchange their Ordinary Shares for securities or other property deliverable upon the occurrence of
such event or the record date for the determination of such holders if such record date is earlier). 
 8.
Reservation of Shares. The Company will at all times reserve and keep available, solely for the issuance and delivery upon the exercise of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from
time to time shall be issuable upon the exercise of this Warrant. 
 9. Exchange of Warrants. Upon
the surrender by the Registered Holder of any Warrant or Warrants, properly endorsed, to the Company at the principal office of the Company, the Company will, subject to the provisions of Section 3 hereof, issue and deliver to or upon the order
of such Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name of such Registered Holder, calling in the 

 
aggregate on the face or faces thereof for the number of Ordinary Shares called for on the face or faces of the Warrant or Warrants so surrendered. 

10. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company, or (in the case of
mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
 11. No Rights as Shareholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or exercise any rights by virtue hereof as a shareholder of the
Company. 
 12. Additional Rights. Upon exercise of this Warrant, the Registered Holder shall have
and be entitled to exercise the rights granted to the signatories who were holders of the Common Stock issued upon conversion of Jazz Pharmaceuticals, Inc.’s Series BB Preferred Stock under the Investor Rights Agreement. By its receipt of this
Warrant, the Registered Holder agrees to be bound by the Investor Rights Agreement. 
 13. No Fractional
Shares. No fractional shares will be issued in connection with any exercise hereunder. In lieu of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied by the
fair market value of one Ordinary Share on the date of exercise, as determined in good faith by the Company’s Board of Directors. 
 14. Amendment or Waiver. Any term of this Warrant may be amended or waived only by an instrument in writing signed by the Company and the registered holder. 

15. Headings. The headings in this Warrant are for purposes of reference only and shall not limit or
otherwise affect the meaning of any provision of this Warrant. 
 16. Governing Law. This Warrant
shall be governed, construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts of law. 
 17. Survival of Representations. Unless otherwise set forth in this Warrant, the warranties, representations and covenants of the Company and the Registered Holder contained in or made
pursuant to this Warrant shall survive the execution and delivery of this Warrant. 
 18. Transfer:
Successors and Assigns. The terms and conditions of this Warrant shall inure to the benefit of aril be binding upon the respective successors and permitted assigns of the parties provided that they have complied with the terms and conditions
herein. Nothing in this Warrant, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Warrant,
except as expressly provided in this Warrant. 
 19. Counterparts. This Warrant may be executed in
two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument. 
 20. Attorney’s Fees. If any action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any of this Warrant, the prevailing party shall be
entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

 21. Severability. If one or more provisions of this Warrant
are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Warrant, (b) the balance of this Warrant shall be interpreted as if such provision were so excluded and (c) the balance of this Warrant shall be enforceable in accordance with its terms. 

22. Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party
under this Warrant, upon any breach or default of any other party under this Warrant, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default,
or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver,
permit, consent or approval of any kind or character on the part of any party of any breach or default under this Warrant, or any waiver on the part of any party of any provisions or conditions of this Warrant, must be in writing and shall be
effective only to the extent specifically set forth in such writing. All remedies, either under this Warrant or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

23. Notices. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed facsimile if sent during normal business hours of the recipient, or if not, then on the next business day; (iii) one day after
deposit with a nationally (or internationally) recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices to the Company shall be sent to the Company’s principal place of business. All notices
to the Registered Holder shall be sent to the address as set forth on the signature page of this Warrant or at such other address as the Registered Holder may designate pursuant to Section 3(c) by ten (10) days’ advance notice to the
Company. 
 24. Entire Agreement. This Warrant and the documents and agreements referred to herein
(including the Investor Rights Agreement) constitute the entire agreement between the parties hereto pertaining to the subject matter hereof, and any and all other written or oral agreements relating to the subject matter hereof existing between the
parties hereto are expressly canceled. 

  

			
	 JAZZ PHARMACEUTICALS PLC

	
	By:                           
                                         

	Name:	 	
	Title:	 	
	Address:	 	     3180 Porter Drive
     Palo Alto, CA 94304

	
	Fax Number:     (650)496-3781

 Accepted and Agreed: 
 REGISTERED HOLDER 

[                        ]

			
		
	By:    	 	 
		 	 Name:

Title

  

			
	Address:	 	
	
	  
	
	  
		
	Fax Number:	 	 

 [Signature Page to Ordinary Share Warrant] 

 EXHIBIT A  

EXERCISE FORM 
  

	To:	     Jazz Pharmaceuticals plc
                                         
                                         
                      Dated: 

 The undersigned, pursuant to the provisions set forth in the attached Warrant No. [    ], hereby irrevocably elects to (a) purchase __________ Ordinary Shares covered by such
Warrant and herewith makes payment of $ _______________ , representing the full purchase price for such shares at the price per share provided for in such Warrant. 
 The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 4 of the Warrant and by its signature below hereby makes such representations and warranties
to the Company as of the date hereof. 
 By: 

Name: 
 Title: 
 Name of Entity: 

 EXHIBIT B 
 ASSIGNMENT FORM 
 FOR VALUE RECEIVED, 

hereby sells, assigns and transfers all of the rights of the undersigned transferor under the attached Warrant with respect to the number
of Ordinary Shares covered thereby set forth below, unto: 
  

					
	 Name of Assignee
	  	 Address/Fax Number
	  	 No. of Shares

The undersigned transferor represents that it has complied with all of the provisions of the attached Warrant governing
the transfer of such Warrant, including without limitation the provisions of Section 3 thereof, and acknowledges that any purported transfer of all or any part of such Warrant in violation of the terms of the attached Warrant shall be null and
void. 
  

							
				
	Dated:                            
                    	 		 	By:	 	
				
		 		 	Name:	 	
				
		 		 	Title:	 	

 The undersigned transferee of the attached Warrant acknowledges the limitations on
transfer of the attached Warrant, including without limitation those contained in Section 3 thereof, agrees to be bound by the terms of the attached Warrant and the Investor Rights Agreement (as defined in the attached Warrant) to the same
extent as if the undersigned transferee were the initial holder of the attached Warrant, and shall deliver to the Company together with this assignment form a counterpart signature page to the Investor Rights Agreement. 

 

							
				
	Dated:                            
                    	 		 	By:	 	
				
		 		 	Name:	 	
				
		 		 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]